Amylyx Pharmaceuticals
Amylyx Pharmaceuticals' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$123 million. The diluted share count rose 38.8%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Amylyx Pharmaceuticals does
Amylyx Pharmaceuticals is a clinical-stage drug company, which means it has no approved product on the market and is still testing its medicines in people. Its programs target endocrine conditions and neurodegenerative diseases.
Its lead candidate is avexitide, which blocks the receptor for a hormone called GLP-1. It is being studied for post-bariatric hypoglycemia (dangerously low blood sugar after weight-loss surgery) and for congenital hyperinsulinism, a condition in which the body makes too much insulin. The company says there are no approved therapies for the first condition. The U.S. Food and Drug Administration has given avexitide special designations for these uses, and a Phase 3 trial in post-bariatric hypoglycemia is under way at sites in the U.S.
Amylyx stopped selling its earlier product in the U.S. and Canada, so it no longer earns revenue from it. It expects to need substantial new funding to pursue its plans.
Its biggest risks, as it describes them
- It depends heavily on the success of avexitide and its other main candidate, AMX0035.
- It has stopped selling its earlier product and will not return to profit unless a new product succeeds.
- It expects to need substantial new funding, and raising it may dilute shareholders.
- Its reliance on third parties to run trials and make its medicines.
Income statement
Amylyx Pharmaceuticals lost money in fiscal 2025: a net loss of $145 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 96 | 347 | 371 | 176 | 317 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 6.0x | 8.2x | 5.7x | 6.7x | 14.3x |
| Quick ratio | 6.0x | 8.0x | 5.2x | 6.7x | 14.3x |
Cash flow
Projections
Project Amylyx Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $152,183 of Amylyx Pharmaceuticals shares on the open market, and 5 insiders sold $16.4 million, $7.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | James M FratesChief Financial Officer | Sold plan | 20,000 | $30.55 | $611,090 | Form 4 |
| Nov 9, 2026 | Justin B. KleeCo-Chief Executive Officer, Director | Sold plan | 100,000 | $29.84 | $3.0 million | Form 4 |
| Nov 9, 2026 | Joshua B CohenCo-Chief Executive Officer, Director | Sold plan | 100,000 | $29.84 | $3.0 million | Form 4 |
| Nov 9, 2026 | James M FratesChief Financial Officer | Sold plan | 20,000 | $29.83 | $596,652 | Form 4 |
| Sep 10, 2026 | Joshua B CohenCo-Chief Executive Officer, Director | Sold | 30,464 | $32.19 | $980,632 | Form 4 |
| Sep 10, 2026 | Justin B. KleeCo-Chief Executive Officer, Director | Sold | 30,464 | $32.18 | $980,290 | Form 4 |
| Sep 10, 2026 | James M FratesChief Financial Officer | Sold | 10,810 | $32.36 | $349,839 | Form 4 |
| Sep 10, 2026 | Camille L BedrosianChief Medical Officer | Sold | 10,028 | $32.39 | $324,833 | Form 4 |
| Sep 10, 2026 | Gina MazzarielloChief Legal Officer | Sold | 9,536 | $32.46 | $309,548 | Form 4 |
| Jul 10, 2026 | Gina MazzarielloChief Legal Officer | Sold plan | 15,000 | $17.61 | $264,150 | Form 4 |
| Jul 9, 2026 | Gina MazzarielloChief Legal Officer | Sold plan | 15,000 | $18.32 | $274,800 | Form 4 |
| May 21, 2026 | Karen FirestoneDirector | Bought | 3,800 | $13.51 | $51,338 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 1,615.7% | −269.1% | — |
| Altman Z'' | 8.85 | −9.69 | 7.18 |
| Accruals ratio | 8.2% | −37.7% | −8.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | Pass | Fail | — |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | — | — | — |
Compare
Put Amylyx Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals | FY25 | −100.0% | — | — | — | — | — | |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Alkermes | FY25 | −5.2% | 17.2% | 32.5% | — | — | — | Compare |
5 years of figures
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 0 | 22 | 381 | 87 | 0 |
| Revenue growth | — | 7,700.0% | 1,612.9% | −77.1% | −100.0% |
| Gross profit | — | 19 | 355 | 81 | 0 |
| Research and development | 44 | 94 | 128 | 104 | 90 |
| Operating income | −83 | −201 | 39 | −315 | −153 |
| Net income | −88 | −198 | 49 | −302 | −145 |
| Diluted EPS (US$) | −13.35 | −3.39 | 0.70 | −4.43 | −1.53 |
| Diluted shares (millions) | 7 | 58 | 70 | 68 | 95 |
| Cash flow | |||||
| Cash from operations | −75 | −180 | 12 | −168 | −123 |
| Capital expenditure | 0 | 2 | 1 | 0 | 0 |
| Free cash flow | −75 | −182 | 11 | −168 | −123 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 22 | 37 | 33 | 28 |
| Balance sheet at fiscal year end | |||||
| Cash and short-term investments | 96 | 347 | 371 | 176 | 317 |
| Debt incl. finance leases | — | — | — | — | — |
| Total assets | 106 | 392 | 518 | 194 | 333 |
| Total liabilities | 17 | 51 | 84 | 29 | 27 |
| Shareholders' equity | −151 | 341 | 433 | 165 | 305 |
| Margins and ratios | |||||
| Gross margin | — | 86.5% | 93.3% | 93.2% | — |
| Operating margin | −29,013.3% | −905.7% | 10.2% | −360.2% | — |
| Net margin | −30,853.0% | −892.4% | 12.9% | −345.4% | — |
| Free cash flow margin | −26,369.1% | −820.5% | 2.8% | −192.1% | — |
| Rule of 40 (growth + FCF margin) | — | 6,879.5% | 1,615.7% | −269.1% | — |
| Return on capital | — | — | — | — | — |
| Return on equity | — | −209.4% | 12.7% | −100.9% | −61.6% |
| Return on assets | — | −79.8% | 10.8% | −84.9% | −55.0% |
| Net debt to EBITDA | — | — | — | — | — |